Century Therapeutics, Inc.

Century Therapeutics, Inc. is a clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer and autoimmune disease. Its platform is designed to create engineered immune cells, including natural killer and T-cell-based product candidates, with the goal of improving consistency, scalability, and manufacturing control versus donor-derived approaches. The company is still in the development phase and has not generated product sales; its historical revenue has come from collaboration arrangements. Century Therapeutics is building both its pipeline and its own manufacturing capabilities, including a flexible cell therapy facility in Branchburg, New Jersey. The business is highly dependent on advancing a small number of early-stage programs and securing future collaboration or financing support.

−3,8 %

−8,8 %

+1 556,8 %

5.97

5.97

— Century Therapeutics, Inc.
%
Cell therapy product candidates0% Engineered iPSC-derived immune cell therapies in clinical and preclinical development for oncology and autoimmune indications.
Platform technology and R&D services0% Discovery, process development, product characterization, and analytical work supporting the cell therapy pipeline.
Collaboration and license revenue100% Revenue recognized from partner agreements, including option, license, and collaboration arrangements.

Century Therapeutics does not currently sell commercial products to end patients or healthcare providers...

  • Strategic pharmaceutical partnersprimary

    Companies that enter collaboration, option, or license agreements to fund development and gain access to Century's cell therapy programs.

  • Biotechnology collaboration partnersprimary

    Smaller biopharma companies that may co-develop or in-license platform assets to accelerate research and clinical development.

  • Manufacturing and supply partnerssecondary

    Third-party manufacturers and service providers that produce clinical material or support process development for trials.

  • Clinical research ecosystemsecondary

    Investigators, trial sites, and patient recruitment networks that enable execution of early clinical studies.

Century Therapeutics is headquartered in the United States and conducts most of its research, development, and...

  • •United States is the core operating base for R&D and manufacturing
  • •Branchburg, New Jersey facility is the main in-house cell therapy site
  • •Madison, Wisconsin facility is used for clinical supply via FCDI
  • •EU clinical supply capability expanded after QP declaration in 2025
  • •No country-level revenue mix was disclosed in the provided excerpts

Century Therapeutics is focused on advancing a concentrated pipeline of iPSC-derived cell therapies, with CNTY-101...

01
Advance lead clinical and preclinical programsshort-term

The company is highly dependent on a small number of programs, so clinical progress is essential to create value and attract partners.

02
Build internal manufacturing capabilitiesmedium-term

Owning more of the manufacturing process should improve control over timelines, quality, and scalability while reducing reliance on third parties.

03
Secure external funding and collaborationsshort-term

The company expects to need additional financing and future collaboration revenue to support ongoing R&D and clinical work.

Century Therapeutics faces the classic risks of a clinical-stage biotech company: its pipeline is concentrated in a...

high

Pipeline concentration in a small number of early-stage programs

The company states that failure to advance its limited preclinical and clinical programs would materially harm the business.

Scope
CNTY-101, CNTY-813, CNTY-308
Materiality
high
high

Need for additional financing

Century expects to raise more capital to fund preclinical studies, clinical trials, and commercialization activities.

Scope
Equity dilution, debt availability, runway risk
Materiality
high
high

Loss of collaboration revenue

Historical revenue came from the Bristol-Myers Squibb collaboration, which was terminated effective March 12, 2025.

Scope
Near-term revenue replacement and partner dependence
Materiality
high
medium

Manufacturing and supply-chain complexity

Cell therapy production requires cGMP compliance, cryopreservation control, and reliable clinical supply across sites.

Scope
Branchburg facility, FCDI supply, EU clinical logistics
Materiality
high
medium

Competitive pressure from larger and better-funded peers

Competitors may reach regulatory approval faster or develop more effective therapies, reducing Century's commercial opportunity.

Scope
Oncology and autoimmune cell therapy markets
Materiality
high
Collaboration revenue recognition
Quarterly revenue volatility and timing differences
Research and development expense recognition
High operating loss volatility
Prepaid expenses and accrued R&D
Period-to-period comparability
Estimates for early-stage development costs
Judgment-sensitive expense recognition

FATE THERAPEUTICS INC

FATE · Biological Products, (No Diagnostic Substances)

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Lineage Cell Therapeutics, Inc.

LCTX · Biological Products, (No Diagnostic Substances)

: 28/04/2026